{"id":"W4402559945","doi":"10.1016/j.annonc.2024.08.776","title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Yakult Honsha; Servier; Kyowa Hakko Kirin; Ipsen; BeiGene; Clovis Oncology; Minderoo Foundation; Ono Pharmaceutical; Eisai; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Endometrial cancer; Ovarian cancer; Gynecology; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000406226,0.0004777168,0.0007760881,0.0002012493,0.000175037,0.0005168031,0.0002403477,0.0003515418,0.002205049],"category_scores_gemma":[0.0003043541,0.000186648,0.0007219001,0.0003540595,0.0002334399,0.0002339948,0.0001455258,0.0008155055,0.0003867058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004781885,"about_ca_system_score_gemma":0.000582692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001555357,"about_ca_topic_score_gemma":0.006520719,"domain_scores_codex":[0.9998646,0.00006624968,0.000007083216,0.00001756778,0.00001496919,0.00002955284],"domain_scores_gemma":[0.9998572,0.00003323748,0.00003206951,0.00001112674,0.000009474001,0.00005697502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5049868,0.01090069,0.05645549,0.001533622,0.004192935,0.0003137876,0.0001912401,0.00330744,0.04886906,0.0005039175,0.009234294,0.3595108],"study_design_scores_gemma":[0.4543998,0.2845174,0.2154257,0.000291227,0.00542649,0.001176161,0.0002725912,0.003196335,0.009081775,0.0006161869,0.0255195,0.00007691347],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874712,0.007631607,0.0001573169,0.0004174637,0.00007432059,0.0002126777,0.001334003,0.00004019877,0.002661332],"genre_scores_gemma":[0.9862765,0.006470389,0.000486518,0.0007387879,0.00007174854,0.0001933099,0.003375279,0.00001645442,0.002371019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002205049,"threshold_uncertainty_score":0.007376611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09096058962015123,"score_gpt":0.4112799389509216,"score_spread":0.3203193493307703,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}